In The News Posted June 12, 2019 Share Posted June 12, 2019 The partnership will leverage Tessa Therapeutics' global operational capabilities and cell therapy platform technologies to target prevalent cancers in China The joint venture will be the sole licensee of Tessa Therapeutics' cell therapies for research, development and commercialization... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.